- Berberine is often marketed as a supplement that can “support metabolism” and reduce fat, but strong clinical evidence matters more than marketing.
- In a large trial involving adults with obesity and fatty liver disease who did not have diabetes, berberine did not reduce visceral belly fat or liver fat more than a placebo after six months.
- Some blood markers improved, but the headline result is blunt: it was not a meaningful fat-loss treatment in this setting.
Excess body fat is not all the same. Visceral fat is stored deep in the abdomen around organs and is linked to insulin resistance, inflammation and higher cardiometabolic risk.
Liver fat, now commonly described under the umbrella of metabolic dysfunction-associated steatotic liver disease, is also tied to long-term risks affecting the heart, blood vessels and metabolic health.
Because these fat depots are more strongly associated with disease than subcutaneous fat under the skin, researchers increasingly measure them directly rather than relying only on weight or body mass index.
Medications such as GLP-1 receptor agonists can reduce visceral fat and liver fat, but they can be expensive and side effects can limit long-term use.
That creates a market for alternatives, including plant-derived compounds. Berberine is a bioactive alkaloid found in several plants and is proposed to influence cellular energy pathways involved in glucose and fat metabolism.
Small studies and mechanistic research have led to claims that it can improve metabolic health, but it has been less clear whether it meaningfully reduces deep abdominal fat and liver fat in people without diabetes.
To address that uncertainty, researchers ran a multicentre, double-blind randomised placebo-controlled trial in China.
Adults with obesity and metabolic dysfunction-associated steatotic liver disease were assigned to oral berberine or a placebo for six months.
Importantly, the main outcomes were measured objectively using imaging.
Computed tomography scans were used to assess visceral adipose tissue area and liver fat content at baseline and again at six months. Imaging was read by radiologists who did not know which treatment each participant received, reducing the risk of biased interpretation.
- GLP1 weight loss drugs linked to small rise in chronic cough
- Daily GLP1 pill helps people lose around 10% of their body weight
- Most adults stop GLP1 therapy within a year
The study enrolled 337 participants, split roughly evenly between the two groups.
Average age was in the early forties and about two thirds were men. The average waist circumference was well into the range associated with increased cardiometabolic risk.
Adherence was high in both groups, which strengthens the conclusions because it reduces the chance that a negative result is simply due to people not taking the product.
The results were straightforward.
Visceral fat did not fall more in the berberine group than in the placebo group. Liver fat also did not improve more with berberine.
In fact, the average changes in liver fat content slightly favoured placebo, though the key point is that there was no statistically meaningful between-group difference.
Put simply, berberine did not outperform placebo on the outcomes that most directly reflect the “belly fat” and “fatty liver” claims.
That does not mean the supplement did nothing at all. The berberine group showed larger reductions in certain blood markers, including LDL cholesterol, apolipoprotein B and high-sensitivity C-reactive protein.
Those findings suggest berberine may have modest effects on lipids and inflammation in some people.
The study also looked at participants with prediabetes at baseline and found no clear difference in remission to normal glucose status between groups.
Safety signals were mixed. Serious adverse events were uncommon in both groups, but slightly more frequent in the berberine group.
Non-serious adverse events of interest were also a bit more common with berberine. That pattern does not automatically mean berberine is dangerous, but it underlines why “natural” is not a synonym for “risk-free”, especially at higher doses over months.
- Nature’s Ozempic: how effective is berberine for weight loss?
- Weight loss surgery outperforms GLP-1 drugs in real-world use
- Boosting GLP-1: how to increase GLP-1 levels naturally
So what should a reader do with this? First, it should temper expectations. If your goal is to reduce visceral fat and liver fat, this trial suggests berberine is unlikely to be the lever that does it, at least not in a clinically meaningful way on its own. Second, it highlights the importance of measuring the right outcomes.
A small change in cholesterol markers may be useful, but it is not the same as the deep fat reduction many people are hoping for.
Finally, there is the real-world issue of supplements.
Products vary in purity and dose and they can interact with medicines.
If someone is considering berberine for metabolic reasons, it is sensible to treat it like a drug rather than a harmless add-on and to discuss it with a clinician or pharmacist, particularly if they take other medications or have liver or kidney problems.
The most honest conclusion from this study is that berberine should not be sold to the public as an evidence-based way to reduce belly fat or fatty liver, because on the strongest available measures it did not deliver.
